ArticleCurrent therapeutic research, clinical and experimental2004
Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study.
Article in Current therapeutic research, clinical and experimental, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects.Journal of obesity · 2019Trial
- The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study.Archives of medical science : AMS · 2017Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptin, which has been identified as an antiobesity hormone, regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis. It appears that leptin may be an important factor in obesity management. Orlistat, a pancreatic lipase inhibitor, could reduce fat absorption and promote weight loss due to leptin metabolism.
objectiveThe purpose of this study was to investigate the effects of orlistat therapy on serum leptin levels.
methodsObese women (body mass index [BMI], 30 kg/m(2)) aged 18 to 50 years were randomly assigned to receive 12 weeks of oral treatment with diet-orlistat (120 mg TID) (DO group) or diet-placebo (DP group). During the treatment period, patients were asked to eat a balanced diet of -1200 to 1600 kcal/d. Body composition was determined by bioelectrical impedance. Serum leptin levels were measured using radioimmunoassay at baseline and at study end.
resultsA total of 24 patients entered the study; 14 patients (mean [SE] BMI, 37.7 [1.1] kg/m(2)) received orlistat and 10 patients (mean [SE] BMI, 39.4 [1.3] kg/m(2)) received placebo. Compared with baseline, mean percentages of loss of body weight and fat mass after 12 weeks of treatment were significant in the DO group (9.1% and 14.8%, respectively; both P = 0.001) and in the DP group (9.5% and 17.6%; both P = 0.005). The between-group differences were not statistically significant. Mean (SE) serum leptin levels also decreased significantly after treatment in the DO group (16.2 [1.2] vs 9.0 [1.0] ng/mL; P = 0.001) and in the DP group (19.3 [2.1] vs 9.7 [1.4] ng/mL; P = 0.005). The between-group difference was not statistically significant.
conclusionsIn this study of obese women, orlistat treatment was associated with a similar decrease in body weight, fat mass, and serum leptin levels as placebo over a 12-week period. In this regard, short-term orlistat therapy may not provide an additional effect on serum leptin levels, and reduction in leptin levels were closely related to the decrease in fat mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.